Titan Logix Corp. Reports Fiscal 2025 Financial Results 
Spetz Inc. Announces Corporate Name and Ticker Symbol Change 
Railtown AI Technologies Announces Closing of the Amalgamation with AI Partnerships Corp. 
Element One Reports on Field Program at Union Bay 
DelphX Announces Non-Brokered Unit Private Placement and Warrant Extension Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) — Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company”…
TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical…
Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022
The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30…
ORYZON Collaborates with the CMT Research Foundation in the US
To explore Oryzon’s HDAC6 inhibitors on Charcot-Marie-Tooth disease CMTRF to provide funding for in vivo…
COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022
LONDON, July 26, 2022 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health…
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH ZUG, Switzerland, July…
AGTC Receives Positive Type C Meeting Feedback from the FDA for the Company’s Design and Operating Procedures of its Planned cGMP Manufacturing Facility
— FDA feedback marks a key milestone in the construction of the facility expected to…
Aquestive Therapeutics to Participate in Wedbush PacGrow Healthcare Conference
WARREN, N.J., July 26, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical…
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage…
Virax Biolabs Introduces Monkeypox and Varicella-Zoster Viruses Real-Time PCR Detection Kit
Kits Available in July for Distribution London, United Kingdom, July 26, 2022 (GLOBE NEWSWIRE) —…
Paladin Phase 4 Study Confirms Safety of Durable ILUVIEN® Treatment and Reduces Burden of Care For DME Patients
Data from the recent 0.19 mg FAc implant Phase 4 observational real-world study were presented…
CinCor Pharma Announces Last Patient Randomized in Phase 2 HALO Trial and Initiation of Long-Term Extension Study for Baxdrostat, a Selective Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension
Open Label Extension Study Will Evaluate Baxdrostat for Up to 52 Weeks Topline Data for…
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2022 Financial Results
FLORHAM PARK, N.J., July 26, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
Spectral Medical’s Chief Medical Officer, Dr. John Kellum, to be the Featured Speaker in Webinar Hosted by Sepsis Alliance
TORONTO, July 26, 2022 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:…
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the…
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting
JERUSALEM, July 26, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the…
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
– At the highest dose level evaluated to date (Cohort 4, 0.128 mg/kg once daily),…
Rapid Therapeutic Science Laboratories File S1 and completes Mid-Year Strategy Review
DALLAS, July 26, 2022 (GLOBE NEWSWIRE) — Rapid Therapeutics Science Laboratories (OTC: RTSL) (“Rapid Therapeutic”…
Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates
LC-FAOD program to move forward into the next stage of clinical development Enrollment of pivotal…